Skip to content
Sign in

Business opportunities

Who each startup should sell to, sell through, build with, enter a market with or raise from, read from the whole network. Every opportunity comes with its reasoning, the evidence and a first step.

SWC 2026 Top 10

BioSapien

3D-printed biodegradable MediChip implant delivering chemotherapy locally at the tumour site, now in colorectal cancer trials in the UAE.

Open the dossier
Opportunities
4
High confidence
070% and above
Counterparts
4startups and investors
  • Customers 1
  • Co-development 2
  • Investors 1

Customers1

Who could buy, or sell through

Buy oncology real-world data to design the next trial

BioSapien must choose indications, endpoints and sites for its next trials. Cromodata sells de-identified, standardised oncology and imaging datasets from a network of hospitals in five Latin American countries, which can inform recurrence rates and control-arm assumptions and identify candidate trial sites outside the UAE.

30%confidence

Evidence from the records

  • “Clinical trials in colorectal cancer are being conducted in the United Arab Emirates.”
  • “Pipeline for de-identifying and standardizing fragmented clinical records (imaging, oncology) into usable datasets, with secure access.”
If it works
Better-powered trial design and a shortlist of Latin American sites; a named pharma-grade data buyer for Cromodata.
First step
Send Cromodata a data request for colorectal cancer cohorts (surgery, recurrence, chemotherapy regimens) and request a sample dictionary.

Co-development2

An integration or joint product

Polymer platform partnership for next-generation implants

MediChip's performance depends on polymer degradation and release kinetics; Pleryon has proprietary platforms to design and control large synthetic and modified natural polymers for drug delivery and injectable biomaterials. A material-supply or joint-development agreement could extend MediChip's release window or open injectable formats, while giving Pleryon an oncology application outside ophthalmology.

30%confidence

Evidence from the records

  • “3D-printed, biodegradable, slow-release implant that can be attached to any tissue”
  • “Proprietary platforms for designing and controlling the structure of large synthetic and modified natural polymers, for drug delivery and injectable biomaterials.”
If it works
A jointly owned next-generation MediChip formulation and a stronger IP position for both companies.
First step
Hold a CSO-to-CSO call to compare polymer requirements (degradation time, drug loading) against Pleryon's catalogue.

Simulate implant release kinetics before printing

Each formulation iteration of an implant costs months of bench work. Caldera Engine couples physics simulation of macromolecular suspensions with AI to predict material properties; applied to MediChip's polymer-drug matrix it could narrow formulation candidates before wet-lab testing.

20%confidence

Evidence from the records

  • “slow-release implant”
  • “Caldera Engine: physics simulation of macromolecular suspensions coupled with AI to predict material properties.”
If it works
Shorter formulation cycles for MediChip variants and a first published life-science customer for Monte Caldera.
First step
Request a Caldera Engine trial and share one non-confidential polymer formulation for a feasibility simulation.

Investors1

A fund whose thesis fits

Approach a science-first VC for the Series A

BioSapien's next round must fund clinical progress; Breakout backs founders pairing technology with science at Seed and Series A and has a US focus consistent with BioSapien's NSF-funded R&D and Silicon Valley regional win. Breakout led ZymoChem's Series A, offering a warm introduction inside the network.

30%confidence

Evidence from the records

  • “Backs founders pairing technology with science (drug discovery, climate, neurotech, lab automation).”
  • “Breakout Ventures (lead), lululemon, Toyota Ventures, GS Futures, KdT Ventures, Cavallo Ventures”
  • “grant (NSF)”
If it works
A US science-focused co-investor that would de-risk an FDA pathway for MediChip.
First step
Ask ZymoChem's CEO for an introduction to the Breakout partner on his board, with a two-page clinical plan attached.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai

Most promising across the network

587 opportunities analysed
  1. BelliwithGolden Gate VenturesInvestors
    Pitch Series A to an Asia–Middle East early-stage VC

    Belli's revenue base sits exactly in Golden Gate's footprint: Singapore HQ, Southeast Asian carriers and Gulf flag carriers. Golden Gate invests Seed to Series A, the stage Belli is approaching, and already backed BioSapien in the network, which gives a warm founder-to-founder introduction.

    50%
  2. AstrolightwithSeraphim SpaceInvestors
    Series A from a specialist space investor

    Seraphim invests globally in space and deep tech addressing security and resilience, from Seed onwards, and appears among G-Space's investors in the network. Astrolight's dual-use optical links fit that thesis precisely.

    40%
  3. ChonexwithCavallo VenturesInvestors
    Bring an agri CVC into the Series A

    Cavallo Ventures is an agri-focused CVC investing from seed to Series B and backed network member ZymoChem. A strategic agri investor fits Chonex's $6M Series A and can accelerate distribution.

    40%
  4. CredncewithMicrotractionInvestors
    Pitch a pre-seed fund whose ticket matches the round

    Crednce is raising $175,000; Microtraction writes $0.1–0.35M pre-seed tickets in Africa with FinTech in its sectors and Ghana in its geographies. The ticket and stage fit are exact, which is rare for a pre-traction fintech.

    40%
  5. TerraSparkwithSeraphim SpaceInvestors
    Target Seraphim Space for the seed round

    Seraphim invests globally in space and climate deep tech from seed onward, with a resilience thesis that covers energy security. It backed network member G-Space, giving a warm path to a seed lead after the 2026 demonstration.

    40%
  6. Thistle OÜwithNATO DIANAInvestors
    Apply to NATO DIANA with the trial results

    NATO DIANA supports pre-seed and seed dual-use start-ups across Europe and North America, exactly Thistle's stage. Network member Astrolight is in the DIANA programme and can coach the application.

    40%
  7. VenditekwithInnogen Capital VenturesInvestors
    Raise from Innogen Capital via Pulster

    Innogen invests at pre-seed and seed in commerce and retail across El Salvador, Honduras, Guatemala and Latin America. It backed network member Pulster.ai, a warm path and a natural co-operation story.

    40%
  8. Wink BiotherapeuticswithU.S. National Institutes of Health (NIH)Investors
    Apply for NIH SBIR funding

    NIH funds US biotech and medtech via SBIR and backed network members Defined Bioscience, Corticale and Microvitality. Non-dilutive funding fits Wink's $75K capital base.

    40%
  9. General Ammonia Co.withU.S. Department of Energy (DOE)Investors
    Apply for DOE early-stage funding via the Sunchem path

    DOE funds pre-seed and seed climate and deep tech in the US, the natural first money for a lab-to-pilot electrochemistry project. DOE already supports network members Sunchem, ZymoChem and Enexor; Sunchem went through Cyclotron Road / DOE LEEP and can advise on the route.

    40%
  10. Neumic Therapeutics LtdwithIcehouse VenturesInvestors
    Seed round from New Zealand's early-stage investor

    Icehouse invests early in Kiwi founders and keeps backing them internationally, from pre-seed to later stages, and backed Neocrete in the network. A University of Otago spin-off with a Volpara co-founder is squarely in its remit.

    40%
  11. IKI HealthwithMutua Ventures (Mutua Madrileña)Investors
    Pitch Mutua Ventures on prevention for an insurer

    Mutua Ventures is the Spanish insurer-backed CVC investing in HealthTech in Spain and Europe and backed network member Legit.Health. A prevention platform with clinical data matches an insurer's interest in reducing claims.

    40%
  12. Piezo Sonic CorporationwithSBI InvestmentInvestors
    Pitch SBI Investment for a disclosed growth round

    SBI Investment's stated focus covers robotics and hardware at Series A and later in Japan and Asia, matching Piezo Sonic's stage and geography. SBI already backed network member Kauche, which gives a warm intro path inside Champions Network.

    40%
  13. Allergen AlertwithEuropean Innovation Council (EIC / EIC Fund)Investors
    EIC Accelerator for diagnostic deep tech

    The EIC Fund takes strategic risk on European breakthrough MedTech/deep tech from seed, with tickets from $0.55M. Allergen Alert's pre-commercial, hardware-heavy profile is exactly the funding gap it targets; network members Lampsy Health and Leitspalt are EIC-backed and can share application experience.

    35%
  14. AstromewithSeraphim SpaceInvestors
    Pitch Seraphim for the Series A

    Seraphim invests globally in space and deep tech for security and resilience from seed onward. It backed network member G-Space, giving a warm path as Astrome moves into satcom.

    35%
  15. TausiwithAntler East AfricaInvestors
    Pitch Antler East Africa for a pre-seed cheque

    Antler East Africa invests up to $0.1M at pre-seed in East Africa; the global Antler network backed network members ThirdRoc and aimea.ai.

    35%
  16. TerraSparkwithEuropean Innovation Council (EIC / EIC Fund)Investors
    Prepare an EIC Accelerator blended-finance bid

    The EIC Fund backs European breakthrough technologies in space and climate with tickets from €0.5M up to €33M, matching TerraSpark's capital intensity. Network members Leitspalt and Lampsy Health obtained EIC support and can share application know-how.

    35%
  17. Thistle OÜwithCoinvest CapitalInvestors
    Bring Coinvest Capital into the open round

    Coinvest is a Lithuanian pre-seed/seed fund investing in deep tech, robotics and AI across Europe, and it backed network member Astrolight, a dual-use company. A Baltic investor familiar with defence suits Thistle's open first round.

    35%
  18. TRL11withSeraphim SpaceInvestors
    Space-specialist investor for the next round

    Seraphim invests from Seed in space ventures addressing security and resilience globally and is listed among G-Space's investors in the network. TRL11's SSA and RPO imaging fits security-oriented space infrastructure.

    35%
  19. EvoNaturawithSOSVInvestors
    Pitch SOSV, ZymoChem's early backer

    SOSV backs deep tech for planetary health from pre-seed onwards and supported ZymoChem through IndieBio in the network.

    35%
  20. EVR Motors Ltd.withBorgWarnerInvestors
    Strategic investment from an EV drivetrain tier-1

    BorgWarner invests strategically in Mobility and Climate & energy and made a $10M strategic minority investment in Enexor in the network. A compact, low-rare-earth motor topology is directly relevant to a drivetrain supplier, and EVR's Series A is announced as under way.

    35%

Similar profiles

Compatibility score with BioSapien

Scored on needs and offers, market bridge, customer potential, sector synergy and stage. Open a profile to see each dimension.